Dataset Information

High-Throughput Cell Death Assays with Single-Cell and Population-Level Analyses Using Real-Time Kinetic Labeling (SPARKL).

ABSTRACT: High-throughput cytostatic and cell death assays are a critical component of pharmacological screens and mechanism-based interrogations into cellular biology. We developed a method for single-cell and population-level analyses using real-time kinetic labeling (abbreviated "SPARKL") with non-toxic fluorescent probes and high-content live-cell imagers. The protocols herein detail the steps, specifics, and suggested utilization of the SPARKL method within several "label-and-go" zero-handling workflows. For complete details on the use and execution of this protocol, please refer to Gelles et al. (2019).

SUBMITTER: Gelles JD

PROVIDER: S-EPMC7423019 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

High-Throughput Cell Death Assays with Single-Cell and Population-Level Analyses Using Real-Time Kinetic Labeling (SPARKL).

Gelles Jesse D JD Chipuk Jerry E JE

STAR protocols 20200603 1

High-throughput cytostatic and cell death assays are a critical component of pharmacological screens and mechanism-based interrogations into cellular biology. We developed a method for single-cell and population-level analyses using real-time kinetic labeling (abbreviated "SPARKL") with non-toxic fluorescent probes and high-content live-cell imagers. The protocols herein detail the steps, specifics, and suggested utilization of the SPARKL method within several "label-and-go" zero-handling workfl ...[more]

PMID: 32793892

Similar Datasets

Project description:A growing understanding of the molecular interactions between immune effector cells and target tumor cells, coupled with refined gene therapy approaches, are giving rise to novel cancer immunotherapeutics with remarkable efficacy in the clinic against both solid and liquid tumors. While immunotherapy holds tremendous promise for treatment of certain cancers, significant challenges remain in the clinical translation to many other types of cancers and also in minimizing adverse effects. Therefore, there is an urgent need for functional potency assays, in vitro and in vivo, that could model the complex interaction of immune cells with tumor cells and can be used to rapidly test the efficacy of different immunotherapy approaches, whether it is small molecule, biologics, cell therapies or combinations thereof. Herein we report the development of an xCELLigence real-time cytolytic in vitro potency assay that uses cellular impedance to continuously monitor the viability of target tumor cells while they are being subjected to different types of treatments. Specialized microtiter plates containing integrated gold microelectrodes enable the number, size, and surface attachment strength of adherent target tumor cells to be selectively monitored within a heterogeneous mixture that includes effector cells, antibodies, small molecules, etc. Through surface-tethering approach, the killing of liquid cancers can also be monitored. Using NK92 effector cells as example, results from RTCA potency assay are very well correlated with end point data from image-based assays as well as flow cytometry. Several effector cells, i.e., PBMC, NK, CAR-T were tested and validated as well as biological molecules such as Bi-specific T cell Engagers (BiTEs) targeting the EpCAM protein expressed on tumor cells and blocking antibodies against the immune checkpoint inhibitor PD-1. Using the specifically designed xCELLigence immunotherapy software, quantitative parameters such as KT50 (the amount of time it takes to kill 50% of the target tumor cells) and % cytolysis are calculated and used for comparing the relative efficacy of different reagents. In summary, our results demonstrate the xCELLigence platform to be well suited for potency assays, providing quantitative assessment with high reproducibility and a greatly simplified work flow.

Dataset Information

High-Throughput Cell Death Assays with Single-Cell and Population-Level Analyses Using Real-Time Kinetic Labeling (SPARKL).

Publications

High-Throughput Cell Death Assays with Single-Cell and Population-Level Analyses Using Real-Time Kinetic Labeling (SPARKL).

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets